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VegfaMiR-185 expression has been associated with many cancers. However, the roles of miR-185 in
human breast cancer remain elusive. Here, we found that miR-185 expression was decreased in
human breast cancer tissues compared with healthy tissue controls. Up-regulation of miR-185
inhibited breast cancer cell proliferation and invasion and vice versa. MiR-185 was shown to bind
to the 30-untranslated region (UTR) of vascular endothelial growth factor a (Vegfa), and a signiﬁcant
inverse correlation was found between miR-185 and Vegfa. Vegfa overexpression partially restored
the inhibition of cell proliferation and invasion that was induced by miR-185, and vice versa. Addi-
tionally, Vegfa expression was found to be high in human breast cancer tissues. Thus, miR-185-med-
iated Vegfa targeting may be involved in breast cancer formation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are small non-protein-coding RNAs that
negatively regulate gene expression by inhibiting the translation
or reducing the stability of target mRNAs [1]. Many miRNAs are
differentially expressed in breast cancers tissues as compared to
adjacent normal breast tissues by high-throughput miRNA expres-
sion proﬁling [2–4]. For example,miR-124was dramatically down-
regulated in breast cancer tissues in human [5]. The proliferative
and invasive ability in ERa-positive and ERa-negative breast can-
cer cells were inhibited by miR-196a2⁄ expression and enhanced
by miR-196a2⁄ antagonism [6].
MiR-185 takes part in a series of cellular activities, such as cell
proliferation and tumorigenesis [7–9]. In recent years, increasing
studies mainly focus on its possible roles in tumorigenesis. Xianget al. found that miR-185 was markedly down-regulated in the cis-
platin-resistant ovarian cancer cells. Moreover, the up-regulation
of miR-185 increased the sensitivity of ovarian cancer cells to cis-
platin-induced apoptosis via altering the DMNT1 expression [7].
In poor survival and metastasis colorectal cancer, miR-185 was
observably up-regulated [8]. Ectopic expression of miR-185 could
suppress the growth of human non small cell lung cancer cell lines
and induce G1 cell cycle arrest in H1229 cells [9]. However, little is
known about the pathophysiological signiﬁcance of miR-185 in
breast cancer.
In order to investigate the molecular mechanisms by which
miR-185 may execute in breast cancer, its target genes were
searched. TargetScan and miRanda prediction algorithms revealed
many possible miR-185 targets. Among them, we found that there
was a highly conserved miR-185 responsive element in 30-untrans-
lated region (30-UTR) of Vegfa. It was reported that Vegfa was a key
regulator in angiogenesis and highly expressed in tumor tissues.
Furthermore, it closely associates with tumor aggressive features
[10,11]. Serum VEGFA concentrations had been elevated in
patients with locoregional ductal cancers compared with women
with benign breast cancer. The patients with metastatic breast
tumor would receive the highest concentrations of serum VEGFA,
in particular among patients who did not obtain cancer therapy
[12]. Thus, we speculate that Vegfa may be the target gene of
miR-185.
R. Wang et al. / FEBS Letters 588 (2014) 4438–4447 4439In this study, the expression pattern of miR-185 and its target
gene Vegfa was evaluated in breast cancer tissues and adjoining
normal breast tissues. The pathophysiological effects of miR-185
in breast cancer were researched via in vitro cell model. Our study
reveals that the miR-185may be a novel biomarker for the diagno-
sis and therapy to human breast cancer in the future.
2. Materials and methods
2.1. Tissue samples and breast cell lines
Human breast cancer tumor tissues and adjacent normal tissues
were acquired from the Third Afﬁliated Hospital of Harbin Medical
University (Harbin, China). Table 1 summarized the clinicopatho-
logic characteristics of patients with breast tumors. Before initia-
tion of the study, we obtained the approval of the Ethics
Committee of National Research Institute for Family Planning
(No. 2011–12) and informed consent from patients. Sixty pairs of
human breast cancer tissues and adjoining normal tissues were
collected. Partial tissues were ﬁxed with 4% paraformaldehyde
solution (Sigma–Aldrich) for in situ detection, and partial tissues
were frozen in liquid nitrogen for RNA and protein analysis.
Human breast carcinoma cell lines T47D, MCF-7, MDA-MB-231
and MDA-MB-453 were acquired from Shanghai Institute of Bio-
chemistry and Cell Biology (Shanghai, China). These cells were cul-
tured in Dulbecco’s Modiﬁed Eagle Medium (DMEM) containing
10% fetal bovine serum (FBS), 100 IU/ml penicillin and 10 mg/mlTable 1
Clinicopathologic characteristics of patients and breast tumors.
Clinical parameters Cases (n = 60) Control (n = 60)
ER PR HER2
ER(+)/PR(+)/HER2(+) 14 (60) 14 (60)
ER()/PR()/HER2() 15 (60) 15 (60)
ER(+)/PR(+)/HER2() 19 (60) 19 (60)
ER()/PR()/HER2(+) 12 (60) 12 (60)
Tumor size (cm)
62 26 (60) 26 (60)
>2 34 (60) 34 (60)
No. of positive lymph nodes
0 29 (60) 29 (60)
1–3 13 (60) 13 (60)
>3 18 (60) 18 (60)
TNM stage
I 9 (60) 9 (60)
II 39 (60) 39 (60)
II–III 5 (60) 5 (60)
III 7 (60) 7 (60)
Table 2
Primer sequences.
Gene name Primer sequence
Vegfa 30-UTR (sense) Forward/SpeI: 50-GGACTAGTGATGTATCTTTTGCTCTCTCTTGCTC
Reverse/PstI: 50-AACTGCAGCTGCACTAGAGACAAAGACGTGATG
VEGF-pGL3-mutant1 Forward: 50-TAAAATTCATGTTTCCAATCTCTATATAACTGATCGG
Reverse: 50-TTATATAGAGATTGGAAACATGAATTTTATATACAAA
VEGF-pGL3-mutant2 Forward: 50-AGAATTCTACATACTAAATCTATATAATTTTTTAATTT
Reverse: 50-TTATATAGATTTAGTATGTAGAATTCTCTATTTTTTCT
VEGFA transcript Forward/XbaI: 50-GCTCTAGAGCATGAACTTTCTGCTGTCTTGGGT
Reverse/XholI: 50-CCCTCGAGGTGCACTAGAGACAAAGACGTGAT
Vegfa Forward: 50-TTTCTGCTGTCTTGGGTGCATTGG-30
Reverse: 50-ACCACTTCGTGATGATTCTGCCCT-30
gapdh Forward:50-GTAGAGGCAGGGATGATGTTC-30
Reverse: 50-TGGTATCGTGGAAGGACTCA-30streptomycin. All cells were maintained at 37 C and 5% carbon
dioxide in a humidiﬁed atmosphere.
2.2. Plasmid construction and transfection
The Vegfa 30-UTR were ampliﬁed from human genomic DNA by
PCR using the primers in Table 2. The PCR product was double
digested with Spe I and Pst I, and then cloned into pGL3 control
vector (designated as Vegfa-pGL3). Mutating the binding sites of
miR-185 in the 30-UTR of Vegfa was used as control (designated
as Vegfa-pGL3-Mutant). The VEGFA transcript was ampliﬁed from
total mRNA of human T47D cells by RT-PCR using the primers in
Table 2. The PCR product was double digested with Xba I and Sac
I, and then cloned into PCAGGS-IRES-EGFP (PCA) control vector
(designated PCA-Vegfa). All the constructs were veriﬁed by DNA
sequencing.
Pre-miR control, miR-185 mimic, anti-miR control, miR-185
inhibitor, scramble siRNA control and Vegfa siRNA were synthe-
sized by GenePharma (GenePharma). The sequences for scramble
and Vegfa siRNA were as follows: scramble siRNA, UUCUCCGAAC-
GUGUCACGU-dTdT, Vegfa siRNA, Sense: 50-GGAGUACCCUGA UGA-
GAUCdTdT-30, antisense: 50-GAUCUCAUCAGGGUA CUCCdTdT-30.
2.3. Quantitative reverse-transcriptase polymerase chain reaction
(qRT-PCR)
Total RNAs were extracted from human breast tissues or cells
using Trizol reagent (Invitrogen). The expression of miR-185 was
detected by TaqMan miRNA RT-Real Time PCR. Total RNAs were
reverse-transcribed by TaqMan MicroRNA Reverse Transcription
Kit (Applied Biosystems). The acquired single-stranded cDNA were
ampliﬁed by TaqMan Universal PCR Master Mix (Applied Biosys-
tems) and miRNA-speciﬁc TaqMan MGB probes: miR-185 and U6
(Applied Biosystems). The U6 was used for internal control. The
expression of Stmn1was detected by RT-Real-time PCR. Total RNAs
were reverse-transcribed by iScriptTM cDNA Synthesis Kit (Bio-
Rad). The single-stranded cDNA were ampliﬁed by a FastStart Uni-
versal SYBR Green Master (Roche) by the primers in Table 2. Glyc-
eraldehyde-3-phosphate dehydrogenase (Gapdh) was used an
endogenous control. Each sample in each group was detected in
triplicate and the experiment was repeated three times.
2.4. Cell proliferation assay
In vitro cell viability was analyzed by MTS assay. MCF-7 and
T47D were transfected with miR-185 mimic and pre-miR control,
respectively. MDA-MB-231and MDA-MB-453 was transfected with
miR-185 inhibitor or anti-miR control. After 48 h of transfection,Accession number Size and location Application
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Fig. 1. Down-regulation of miR-185 in human breast cancer tissues. The cancer
tissues from two patients with similar clinical parameters were pooled as a sample.
MiR-185 level in individual sample was detected by TaqMan miRNA RT-Real Time
PCR (A). The general trend of miR-185 in all human breast cancer tissues was
analyzed by one-way ANOVA (B). The relative level of miR-185 was normalized to
U6. ⁄P < 0.05.
4440 R. Wang et al. / FEBS Letters 588 (2014) 4438–444720 ll MTT (5 mg/ml; Sigma–Aldrich) was added into each well and
incubated for 4 h. The media was removed and each well was wash
three times by phosphate buffered saline (PBS). 150 ll dimethyl
sulfoxide (Sigma–Aldrich) was added into each well and the absor-
bance was measured by a 96-well plate reader (Bio-Rad 3550) at a
wavelength of 570 nm. There were triplicate wells in each treat-
ment group. The experiment was repeated for three times. The cell
proliferation capacity was represented by the ratio of absorbance
with miR-185 mimc or miR-185 inhibitor vs its corresponding
control.
2.5. Flow cytometry analysis
Cells apoptosis was detected by ﬂow cytometry analysis using
Annexin V-FLUOS staining kit (Roche, Mannheim, Germany). Cells
suspension were added with 2.5 ll annexin V-ﬂuorescein isothio-
cyanate (FITC) stock and 5 ll 20 lg/ml phosphatidylinositol (PI).
The mixture was incubated 15 min at room temperature in the
dark. The early and late apoptotic populations were analyzed by
ﬂow cytometry (BD Biosciences). Each sample acquired 8000
events. Each treatment was detected in duplicative and the exper-
iment was repeated for three times.
2.6. In vitro migration and invasion assays
MCF-7 and T47D were transfected with miR-185 mimic or pre-
miR control, respectively. MDA-MB-231 and MDA-MB-453 was
transfected with miR-185 inhibitor or anti-miR control, respec-
tively. After 48 h of transfection, the transfected cells were har-
vested and subjected to the following assays. For migration
assays, the transfected cells (0.5  106 cells/ml) were seeded in
the top of an 8.0-lm-pore membrane chamber (Corning). Cells
were ﬁxed by 4% paraformaldehyde solution (Sigma–Aldrich) and
stained with hematoxylin and eosin (Sigma–Aldrich) after 17 h of
incubation. For invasion assays, matrigel (BD Biosciences) was
added in the top of an 8.0-lm-pore membrane chamber (Corning)
and incubated at room temperature until the matrigel solidiﬁed.
Cells (0.5  106 cells/ml) were seeded on the top of matrigel-
coated membrane. Cells were ﬁxed by 4% paraformaldehyde solu-
tion (Sigma–Aldrich) and stained with hematoxylin and eosin
(Sigma–Aldrich) after 24 h of incubation. Cells through membrane
were counted under a light microscope. The amount of cells pass-
ing through the membrane from ﬁve different ﬁelds per sample at
200 selected in a random manner was used to determine the
capacity of cell migration or invasion.
2.7. Dual-luciferase activity assay
T47D cells were seeded in 48-well plates at a density of 1  105,
and then transfected by lipofectamine 2000 (Invitrogen) according
to the manufacture’s instruction. pRL-TK containing Renilla lucifer-
ase was used for normalization of gene expression in transiently
transfected cells. After 48 h of transfection, cells were harvested.
The luciferase activity was analyzed by the dual-luciferase kit (Pro-
mega). Each treatment was detected in triplicate and the experi-
ment was repeated for three times. The results were expressed
as relative luciferase activity (Fireﬂy LUC/Renilla LUC).
2.8. Western blot
The extracted protein samples from human breast tissues or
cells (40 lg) were separated on 12% sodium dodecylsulfate (SDS)
polyacrylamide gels and electrotransferred onto polyvinylidene
ﬂuoride membrane (PVDF) (Amersham Pharmacia Biotech). The
membrane was incubated with primary antibodies anti-VEGFA
(Cell Signaling Technology) or anti-GAPDH (Santa Cruz Biotechnol-ogy Inc.) overnight at 4 C. Then the membrane was incubated with
horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG
(Jackson Immunoresearch Laboratories, Inc.). The bands were visu-
alized with the ECL kit (Millipore). GAPDH was used as an internal
control. The experiment was repeated at least three times.
2.9. Statistical analysis
All statistical analyses were performed using SPSS 16.0. All val-
ues are reported as the mean ± S.E.M. One-way analysis of variance
(ANOVA) was used to perform multiple group comparisons. A lin-
ear correlation assay was performed using Pearson correlation. Dif-
ferences were considered statistically signiﬁcant at P < 0.05.
3. Results
3.1. The expression proﬁles of miR-185 in human breast cancer tissues
To investigate the role of miR-185 in the occurrence of human
breast cancer, we analyzed the expression proﬁles of miR-185 in
60 pairs of human breast cancer tissues and adjoining normal
breast tissues by qRT-PCR (Table 1 and Fig. 1). In order to reduce
individual difference of the samples, we pooled cancer tissues form
two patients with similar clinical characteristics as a sample (30
samples for 60 pairs). The expression level ofmiR-185was dramat-
ically reduced in 70% (21/30 samples) of breast cancer tissues
(Fig. 1A). When compared with compared with adjoining normal
tissues, miR-185 level was obviously diminished in all human
breast cancer tissues (P < 0.01; Fig. 1B).
3.2. MiR-185 regulates breast cancer cells proliferation in vitro
In order to ﬁgure out the possible functions of miR-185 in the
pathological progression of breast cells, we detected the effect of
miR-185 on the growth of breast cancer cells. To choose appropri-
ate cell lines to execute over-expression and knockdown of miR-
185, we ﬁrstly detected the endogenous miR-185 level in MCF-7,
R. Wang et al. / FEBS Letters 588 (2014) 4438–4447 4441T47D, MDA-MB-453and MDA-MB-231 cells by qRT-PCR. The miR-
185 level in MDA-MB-231 was higher than that in MCF-7
(P < 0.01) and T47D (P < 0.01), but approximate with that in
MDA-MB-453 (Fig. S1). After that, the effect of miR-185 mimic or
inhibitor on miR-185 expression in these cancer cell lines was
detected by qRT-PCR. Compared with pre-miR control, miR-185
mimic markedly enhanced miR-185 level (P < 0.01), and miR-185
inhibitor obviously reduced miR-185 expression compared with
pre-miR control (Fig. S2; P < 0.01).
The cell proliferation in miR-185 mimic or inhibitor-treated
cells was detected by MTT assay after 48 h of transfection
(Fig. 2). Compared with pre-miR control, the relative proliferation
rates inmiR-185mimic-treated MCF-7 and T47D cells were respec-
tively decreased about 15.95% and 13.75% (P < 0.05). However, the
relative proliferation rates in miR-185 inhibitor-treated MDA-MB-
231 and MDA-MB-453 cells were respectively increased about
21.82% and 17.5% (P < 0.05). All these facts show that over-expres-
sion of miR-185 can inhibit the proliferation of breast cancer cells,
while low expression ofmiR-185 obviously facilitates breast cancer
cells viability.
3.3. MiR-185 affects breast cancer cells apoptosis in vitro
Cell apoptosis in four breast cancer cells was detected by ﬂow
cytometry in order to further investigate the role ofmiR-185 in reg-
ulating the growth of breast cancer cells (Fig. 3). Compared with
pre-miR control, the number of early apoptotic cells were
enhanced by miR-185 mimic in T47D (3.43% vs 1.62%), MCF-7
(13.94% vs 9.43%). The number of late apoptotic cells was aug-
mented in T47D (4.57% vs 1.60%), and there was not signiﬁcant dif-
ferent in MCF-7 cells. Compared with anti-miR control, miR-185
inhibitor reduced the number of early apoptotic cells in MDA-
MB-231 (12.53% vs 17.22%) and MDA-MB-453 cells (5.25% vs
9.84%). The number of late apoptotic cells had no obviousA
B
Fig. 2. Cell proliferation in breast cancer cells.MiR-185mimic and/or PCA-Vegfa or empty
185 inhibitor and/or Vegfa siRNA or scramble siRNA control were/was respectively tr
proliferation was determined by MTT assay. All experiments were performed at least thr
miR-185 mimic or miR-185 mimic + PCA; ⁄c: miR-185 inhibitor vs anti-miR control; ⁄d: m
siRNA. ⁄P < 0.05.difference. These results indicate that over-expression of miR-185
can promote cell apoptosis and low expression of miR-185 inhibits
cell apoptosis at early stage.
3.4. MiR-185 regulates the capacity of breast cancer cells migration
and invasion in vitro
The inﬂuence of miR-185 on migration and invasion of breast
cancer cells were detected in order to further explore the role of
miR-185 in modulating the of breast cancer cells metastasis (Figs. 4
and 5). Compared with pre-miR control, miR-185 mimic dramati-
cally decreased the capacity of cell migration in T47D and MCF-7
cells (P < 0.05). The migration capacity was signiﬁcantly higher in
miR-185 inhibitor-treated MDA-MB-231 and MDA-MB-453 cells
than corresponding control (Fig. 4; P < 0.05). Furthermore, the
capacity of invasion assay revealed that miR-185 mimic signiﬁ-
cantly inhibited the invasive capacity of MCF-7 and T47D cells
compared with pre-miR control (P < 0.05). However, the invasive
ability was obviously increased in miR-185 inhibitor-treated
MDA-MB-231 and MDA-MB-453 cells (Fig. 5; P < 0.05). These
results indicate that the expression level ofmiR-185may be closely
related with breast cancer cells metastasis.
3.5. Vegfa is a target gene of miR-185
To conﬁrm whether Vegfa is target gene of miR-185, the dual-
luciferase assay was used to analyze the relationship between
miR-185 and human Vegfa 30-UTR fragment containing the binding
sites ofmiR-185 (Fig. 6A). Vegfa-pGL3 andmiR-185mimic or inhib-
itor were co-transfected into to T47D cells (Fig. 6B). The luciferase
activity was decreased about 44.19% by miR-185 mimic (P < 0.05)
compared with the pre-miR control. Additionally, the luciferase
activity was increased about 88.34% by miR-185 inhibitor when
compared with the anti-miR control, (P < 0.01). These ﬁndingsvector control PCA were/was respectively transfected into MCF-7 or T47D (A).MiR-
ansfected into MDA-MB-231 or MDA-MB-453 (B). After 48 h of transfection, cell
ee times. ⁄a: miR-185 mimic vs pre-miR control; ⁄b: miR-185 mimic + PCA-Vegfa vs
iR-185 inhibitor + Vegfa siRNA vs miR-185 inhibitor vs miR-185 inhibitor + Scramble
AB
Fig. 3. Apoptosis in breast cancer cells. MiR-185 mimic and/or PCA-Vegfa or empty vector control PCA were/was transfected into MCF-7 or T47D (A), and miR-185 inhibitor
and/or Vegfa siRNA or scramble siRNA control were/was transfected into MDA-MB-231 or MDA-MB-453 (B). After 48 h of transfection, single cell suspension was prepared
and stained with annexin V/PI and subjected to ﬂow cytometry analysis. Lower left quadrant, viable cells (annexin V-FITC and PI negative); lower right quadrant, early
apoptotic cells (annexin V-FITC positive and PI negative); upper right quadrant, late apoptosis/necrosis cells (annexin V-FITC and PI positive). The percentage of early and late
apoptotic cells (representatives of three separate experiments) was shown in the lower right and upper right panels, respectively.
4442 R. Wang et al. / FEBS Letters 588 (2014) 4438–4447show that miR-185 has effects on the binding ability of miR-185
and 30-UTR of Vegfa.
Afterwards, we conducted base mutation of seed sequence to
further validate the binding sites formiR-185 (Fig. 6C). PGL3 empty
vector and Vegfa-pGL3-Mutant that mutated the miR-185 binding
sites in the 30-UTR of Vegfa were used as control. Compared with
Vegfa-pGL3-Mutant or pGL3 empty vector, the enzyme activity
was signiﬁcantly decreased in cells co-transfected with miR-185
mimic and Vegfa-pGL3 (P < 0.05). These results show that Vegfa
may be a direct target gene of miR-185 that inhibits Vegfa expres-
sion through binding to seed sequence in Vegfa 30-UTR.
3.6. MiR-185 affects the expression of Vegfa in breast cancer cells
in vitro
T47D cells were transfected with miR-185 mimic or inhibitor to
analyze the effects of miR-185 expression disorder on endogenous
VEGFA expression. VEGFA protein level was signiﬁcantly down-
regulated by miR-185 mimic compared with pre-miR control
(P < 0.05), while miR-185 inhibitor markedly promoted VEGFA
expression (P < 0.05) (Fig. 6D). Furthermore, qRT-PCR was used to
detect Vegfa mRNA level. miR-185 mimic signiﬁcantly decreased
Vegfa mRNA level (P < 0.05), while miR-185 inhibitor markedlyincreased Vegfa mRNA level (P < 0.05) (Fig. 6E). These ﬁndings
show that the mRNA and protein level of endogenous Vegfa can
be regulated by miR-185.
3.7. Vegfa is involved in the inﬂuence of mir-185 on cell viability and
metastasis
We assessed the inﬂuences of Vegfa on miR-185-mediated cell
growth and metastasis in order to further validate whether miR-
185 executed tumor-suppressive functions by targeting Vegfa.
The inﬂuence of Vegfa constructs on Vegfa expression was detected
by qRT-PCR andWestern blot. The mRNA and protein level of Vegfa
was obviously increased by PCA-Vegfa (P < 0.01) and markedly
reduced by Vegfa siRNA (Fig. S3; P < 0.01). Co-transfection of
PCA-Vegfa and miR-185 mimic increased the ability of prolifera-
tion, migration and invasion and decreased the level of apoptosis
compared with miR-185 mimic alone in T47D and MCF7 cells
(Figs. 2A, 3A, 4A and 5A), implying that the up-regulation of Vegfa
could partially rehabilitate the inhibition of cell proliferation and
metastasis mediated by miR-185 overexpression. Additionally,
Co-transfection of Vegfa siRNA and miR-185 inhibitor reduced cell
proliferation, migration and invasion ability and enhanced cell
apoptosis level compared miR-185 inhibitor alone in MDA-MB-
AB
Fig. 4. Cell migration in breast cancer cells. Cells migratory capacity was detected in MCF-7 or T47D cells transfected by miR-185 mimic and/or PCA-Vegfa or empty vector
control PCA (A), and in MDA-MB-231 or MDA-MB-453 transfected bymiR-185 inhibitor and/or Vegfa siRNA or scramble siRNA control (B). Cells that had migrated to the ﬁlter
bottom were quantiﬁed by counting the amount of cells passing through the membrane from ﬁve different ﬁelds per sample at 200 selected in a random manner. A and B
show the representative photomicrographs of cells passing through the membrane at 200 original magniﬁcation. Histogram A1, A2, B1 and B2 represent the number of
migrated cells in MCF-7, T47D, MDA-MB-231 and MDA-MB-453 cells, respectively. Data are expressed as the mean numbers of independent triplicate experiments. ⁄a: miR-
185 mimic vs pre-miR control; ⁄b: miR-185 mimic + PCA-Vegfa vs miR-185 mimic or miR-185 mimic + PCA; ⁄c: miR-185 inhibitor vs anti-miR control; ⁄d: miR-185
inhibitor + Vegfa siRNA vs miR-185 inhibitor vs miR-185 inhibitor + Scramble siRNA. ⁄P < 0.05.
R. Wang et al. / FEBS Letters 588 (2014) 4438–4447 4443231 and MDA-MB-435 cells (Figs. 2B, 3B, 4B and 5B), displaying
that miR-185 knockdown-mediated the facilitation of cell viability
and metastasis was partly attenuated by down-regulation of Vegfa.
These ﬁndings reveal that miR-185 carries out functions in breast
cancer cells partly by regulating Vegfa.
3.8. Vegfa expression in human breast cancer tissues
We detected the protein and mRNA level of Vegfa in breast can-
cer tissues by Western blot and qRT-PCR in order to further inves-tigate the expression pattern of miR-185 target gene Vegfa in vivo,
(Fig. 7). The protein level of VEGFA was dramatically enhanced in
breast cancer tissues (Fig. 7A; P < 0.05). Additionally, Vegfa mRNA
level was obviously augmented in 80% (24/30 samples) of breast
cancer tissues (Fig. 7B). When compared with that in adjacent nor-
mal breast tissues, the general trend of Vegfa in all human breast
cancer tissues was increased (Fig. 7B1; P < 0.05). The expression
proﬁles of Vegfa is inverse with miR-185 in breast cancer tissues,
suggesting that miR-185 may take part in the occurrence of breast
cancer by targeting Vegfa in vivo.
AB
Fig. 5. Cell invasion in breast cancer cells. Cells invasive capacity was detected in MCF-7 or T47D cells transfected by miR-185 mimic and/or PCA-Vegfa or empty vector
control PCA (A), and in MDA-MB-231 or MDA-MB-453 transfected bymiR-185 inhibitor and/or Vegfa siRNA or scramble siRNA control (B). Cells that had migrated to the ﬁlter
bottom were quantiﬁed by counting the amount of cells passing through the membrane from ﬁve different ﬁelds per sample at 200 selected in a random manner. A and B
show the representative photomicrographs of cells passing through the membrane at 200 original magniﬁcation. Histogram A1, A2, B1 and B2 represent the number of
invaded cells in MCF-7, T47D, MDA-MB-231 and MDA-MB-453 cells, respectively. Data are expressed as the mean numbers of independent triplicate experiments. ⁄a: miR-
185 mimic vs pre-miR control; ⁄b: miR-185 mimic + PCA-Vegfa vs miR-185 mimic or miR-185 mimic + PCA; ⁄c: miR-185 inhibitor vs anti-miR control; ⁄d: miR-185
inhibitor + Vegfa siRNA vs miR-185 inhibitor vs miR-185 inhibitor + Scramble siRNA. ⁄P < 0.05.
4444 R. Wang et al. / FEBS Letters 588 (2014) 4438–44473.9. The correlation between miR-185 and Vegfa in human breast
cancer tissues
In order to further demonstrate the relationship between miR-
185 andVegfa, a linear correlation assaywas carried out by SPSS16.0.
Different housekeeping genes were used as control for normaliza-
tion of miR-185 and Vegfa expression. In order to decrease experi-
ment error, we adopted the ratio of miR-185 or Vegfa in breast
cancer tissues vs adjacent normal breast tissues to execute the linearcorrelation assay. A signiﬁcant inverse correlation was found
between miR-185 and Vegfa on human breast cancer tissues
(Fig. 8; P < 0.01). The Pearson Correlation Coefﬁcient is 0.573.
4. Discussion
In this study, we provided the ﬁrst evidence of the association of
miR-185 and breast cancer, although some studies had showed that
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R. Wang et al. / FEBS Letters 588 (2014) 4438–4447 4445miR-185 participated in ovarian cancer, colorectal cancer, non
small cell lung cancer and so on [7–9,13,14].
In this study, we found thatmiR-185was dramatically increased
in breast cancers tissues when compared with that in adjoining
normal tissues. It suggests that miR-185 may take part in breast
carcinogenesis.
We further explore the roles of miR-185 in the occurrence of
breast cancer. Over-expression of miR-185 in human breast cancer
cell lines accelerated apoptosis and suppressed cells proliferation,
invasion and migration, and vice versa. It had been reported that
overexpression ofmiR-185 in ovarian cells could inhibit the growth
of cells and promote cellular apoptosis [7]. The differential expres-
sion of miR-185 inhibited the growth of non-small lung cancer
cells, lead to the arrest of cell cycle [9]. The roles miR-185 in breast
cancer are similar with that in other cancers. All of these results
imply that miR-185may act as tumor suppressor in the occurrence
of cancer.It is generally accepted that miRNAs carry out their function by
modulating the expression of their target genes. Vegfa is a member
of the Vegf family, which is the most critical driver of vascular for-
mation and required to initiate the formation of immature vessels
in tumor [15–17]. The expression of Vegf was up-regulated in
human breast tumors tissues and negatively inﬂuenced survival
[10,11]. Overexpression of Vegf dramatically reduced tumor uptake
and enhanced tumor growth in a murine model of breast cancer
[16]. Vegf could prevent apoptosis induced by serum starvation
and induce expression of the anti-apoptotic proteins Bcl-2 and
A1 [18,19]. All these facts indicate that Vegfamay be closely related
with the occurrence of breast tumor.
In this study, we explored the target genes of miR-185 and
found a conservative seed sequence in the 30-UTR of Vegfa pre-
dicted by miRanda and Targetscan. MiR-185 mimic and inhibitor
regulated Vegfa 30-UTR-mediated luciferase activity. Mutating seed
sequence in the 30-UTR of Vegfa obviously suppressed the binding
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GAPDH is served as an internal control. The black histograms A1 represent the expression level of VEGFA in all breast cancer tissues. (B) The mRNA level of Vegfa in human
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4446 R. Wang et al. / FEBS Letters 588 (2014) 4438–4447ability of miR-185 and 30-UTR of Vegfa. Additionally, up-regulation
of miR-185 decreased the expression of Vegfa and down-regulationFig. 8. The correlation between miR-185 and Vegfa in human breast cancer tissues.
A linear correlation assay was carried out by SPSS16.0. ⁄⁄P < 0.01.of miR-185 increased the protein and mRNA level of Vegfa in vitro.
A signiﬁcant inverse correlation was also found between miR-185
and Vegfa in human breast cancer tissues. Furthermore, the up-reg-
ulation of Vegfa could partially regain the overexpression of miR-
185-mediated the suppression of cell growth and metastasis. The
inﬂuence of Knockdown of miR-185 on cell growth and metastasis
was weakened down-regulation of Vegfa. Therefore, we conﬁrm
that Vegfa is the target gene of miR-185 and miR-185 may execute
its tumor suppressor function partially by targeting Vegfa.
Divertingly, our results indicated that miR-185 level in breast
cancer cells and breast cancer tissues was all oppositely related
with the Vegfa mRNA level. Usually, miRNAs were supposed to
exert function by inhibiting mRNA translation [20]. However,
recent reports indicated that the alteration in protein level medi-
ated by a miRNA were usually related with the changes of mRNA
level, indicating that mRNA degradation might be a main element
of mammalian miRNA suppression [21,22]. Our ﬁndings were also
consistent with this reports.
R. Wang et al. / FEBS Letters 588 (2014) 4438–4447 4447Because a speciﬁc miRNA usually targets to multiple genes,
miR-185 excert its function may get through synergistic action of
its target genes. In the future, besides Vegfa, other targets of miR-
185 still require to be conﬁrmed in breast cancer. Additionally, ani-
mal experiment may be needed in order to further validate the
function of miR-185 and the relationship between miR-185 and
Vegfa in vivo.
In conclusion,miR-185 is obviously diminished in human breast
cancer tissues, which facilitates breast cancer cell proliferation,
invasion and migration and suppresses cell apoptosis. MiR-185
excerts these functions in breast cancer cell lines partly by regulat-
ing Vegfa. Our data will not only show the potential roles of miR-
185 in breast carcinogenesis, but also provide a clue for diagnosis
and therapeutics of breast cancer.
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